monoclonal antibodies Archive — Page 4 of 9
-
September 8, 2021
VUMC antibodies help neutralize two deadly viruses: study
Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra. -
August 20, 2021
COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today. -
August 19, 2021
Team isolates antibodies that target alphaviruses
A multi-institutional team led by researchers at Vanderbilt University Medical Center has isolated monoclonal antibodies that in laboratory and animal studies prevented infection by alphaviruses, including the often-lethal Eastern equine encephalitis virus (EEEV). -
July 16, 2021
Study identifies monoclonal antibodies that may neutralize many norovirus variants
Researchers at Vanderbilt University Medical Center (VUMC) and the Baylor College of Medicine in Houston, Texas, have taken a big step toward developing targeted treatments and vaccines against a family of viruses that attacks the gastrointestinal tract. -
June 22, 2021
Combination antibody therapies should retain effectiveness against emerging COVID-19 variants: study
Five monoclonal antibody “cocktails,” including one developed at Vanderbilt University Medical Center (VUMC), are protective in animal studies against several variant strains of COVID-19, according to a report this week in the journal Nature. -
April 6, 2021
U.S. government reserves supply of COVID-19 antibody cocktail discovered at VUMC
The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced. -
April 1, 2021
Novel way to neutralize Rift Valley Fever Virus
The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.